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Abstract 
Aberrant phosphoinositide-3-kinase (PI3K), mitogen-activated protein kinase (MAPK) and WNT 
signalling are emerging as key events in the multistep nature of prostate tumourigenesis and 
progression.  Here we report a compound prostate cancer murine model, in which these signalling 
pathways cooperate to produce a more aggressive prostate cancer phenotype. Using Cre-LoxP 
technology and the Probasin promoter, we combined the loss of Pten (Pten
fl/fl
), to activate the PI3K 
signalling pathway, with dominant stabilised β-catenin (Catnb+/lox(ex3)) and activated K-RAS (K-
Ras
+/V12
) to aberrantly activate WNT and MAPK signalling, respectively. Synchronous activation of 
all three pathways (triple mutant) significantly reduced survival (median 96 days) compared to 
double (median 140 days for Catnb
+/lox(ex3)
Pten
fl/fl
; 182 days for Catnb
+/lox(ex3)
K-Ras
+/V12
; 238 days 
for Pten
fl/fl
K-Ras
+/V12
) and single mutant mice (median 383 days for Catnb
+/lox(ex3)
; 407 days for 
Pten
fl/fl
), reflecting the accelerated tumourigenesis. Tumours followed a step-wise progression from 
mouse prostate intraepithelial neoplasia (mPIN) to invasive adenocarcinoma, similar to that seen in 
human disease. There was significantly elevated cellular proliferation, tumour growth and 
percentage of invasive adenocarcinoma in triple mutant mice compared to double and single 
mutants. Triple mutants not only displayed activated AKT, ERK1/2 and nuclear β-catenin but also 
significantly elevated mechanistic target of rapamycin complex 1 (mTORC1) signalling. In 
summary, we show that combined deregulation of the PI3K, MAPK and WNT signalling pathways 
drives rapid progression of prostate tumourigenesis, and that deregulation of all three pathways 
results in tumours showing aberrant mTORC1 signalling. As mTORC1 signalling is emerging as a 
key driver of androgen deprivation therapy resistance, our findings are important for understanding 
the biology of therapy-resistant prostate cancer and identifying potential approaches to overcome 
this. 
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Introduction 
Advanced molecular and genetic technologies have identified a vast number of somatic mutations, 
copy number alterations, and oncogenic structural DNA rearrangements in both primary[1-5] and 
metastatic prostate cancer (PCa)[6-10]. However, these studies, together with the COSMIC 
database (http://cancer.sanger.ac.uk/cosmic), highlight a limited number of highly recurrent 
abnormalities in specific genes/pathways. Recurrent somatic mutations in cell signalling pathways 
or processes that can be clinically actionable/targeted by emerging therapies include for example 
the WNT, phosphoinositide-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) 
signalling pathways. 
Deregulation of WNT signalling is implicated in many cancers. The best known example is 
colorectal cancer, where greater than 90% have an activating mutation of the canonical WNT 
signalling pathway [11]. In PCa, deregulated WNT signalling has been primarily investigated in 
metastatic disease, with somatic alteration of the Adenomatous Polyposis Coli tumour suppressor 
gene (APC) and β-catenin reported in 8.7-19.7% and 4.9-12% of cases, respectively[7,10]. WNT 
signalling has also been implicated in the lethal phase of PCa, castrate resistant prostate cancer 
(CRPC), independent of androgen signalling[6,7]. Up-regulation of the PI3K pathway, 
encompassing multiple somatic alterations such as deletion/mutations in PTEN, PI3K or AKT, has 
been reported in 42% of primary tumours and 100% of metastatic tumours[1] suggesting that this 
pathway plays a key role in the ability of the cancer cell to metastasise. Lastly, aberrations that 
result in the upregulation of the MAPK pathway are also common in PCa, with pathway alterations 
reported in 43% of primary tumours and 90% of metastasis[1]. Furthermore, the MAPK signalling 
pathway has not only been implicated in the initial phase of metastasis but also the late transition to 
CRPC[12]. 
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Historically, signalling pathways have been studied as linear entities that do not interact; however 
the importance of pathway crosstalk which results in complex signalling webs is now understood. 
There is growing appreciation that this crosstalk is key for tumour development and progression. 
We have previously shown in the mouse that the WNT and MAPK pathways synergise to accelerate 
prostate tumourigenesis[13]. Others have demonstrated that canonical WNT signalling promotes 
prostate carcinogenesis driven by FGFR1 (which activates both PI3K and MEK/ERK 
pathways)[14]. The crosstalk between WNT and PI3K pathways in prostate tumourigenesis has 
been shown previously[15] and several studies have investigated synergistic effects between PI3K 
and MAPK pathways in mouse models[16-19].  Mechanisms of c-MYC activation also suggest a 
possible convergence between the WNT, PI3K and MAPK pathways in PCa. c-Myc is an important 
WNT target gene and a key effector of deregulated WNT signalling[20] although can also be 
activated in a WNT-independent manner, as demonstrated in a murine PCa model of Pten deletion 
and mutant B-RAF activation[17].  
We hypothesized that combined deregulation of PI3K, WNT and MAPK signalling would 
cooperate to accelerate prostate tumourigenesis. To test this, we used an in vivo genetics approach 
to combine aberrant PI3K, WNT and MAPK signalling in the mouse prostate[13].  We report here 
that while activating any two of these pathways together accelerates tumourigenesis over single 
pathway activation, combining all three further augments tumour formation, indicating each 
pathway makes a distinct contribution to the process of tumourigenesis. Furthermore, we observed 
strongest mTORC1 activation in triple mutants, consistent with findings from a human PCa tissue 
microarray, suggesting this may be the target of the synergistic activity of these three pathways. As 
mTORC1 signalling is emerging as a key driver of androgen deprivation therapy (ADT) resistance 
and stimulates tumour growth in the setting of castrate levels of testosterone, our findings are 
important for understanding the biology of therapy-resistant PCa and identifying potential 
approaches to overcome this.  
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Materials and Methods 
Experimental animals 
All animal studies and breeding were carried out under UK Home Office regulations following 
local ethical approval and according to the ARRIVE guidelines[21].  Probasin (Pb)-Cre4 mice 
were sourced from the Mouse Models of Human Cancer Consortium (National Cancer Institute-
Frederick).  The alleles used in this study were β-catenin+/lox(ex3 )[22], K-Ras+/V12[23] and 
Pten
fl/fl
[24].  The Pb-Cre4 transgene was incorporated into cohorts using male mice, as Pb-Cre4 
positive female mice have been shown to recombine in the ovaries resulting in a mosaic 
phenotype[25]. Mice were genotyped from DNA isolated from ear nicks. Each loxP-targeted allele 
and the Cre-recombinase transgene were detected as described previously[22-24]. Kaplan–Meier 
survival analysis was carried out using GraphPad Prism (Version 5.0b). Only mice which reached 
specified endpoints when euthanasia was necessary due to prostate disease were included in KM 
curves. 
In some cases, bromodeoxyuridine (BrdU, GE Healthcare, Buckinghamshire, UK) was 
administered via intra-peritoneal injection; mice were euthanized 2 hours post-administration.   
Tissue isolation and histology 
Tissue was harvested and fixed in 10% neutral buffered formaldehyde at 4°C for no more than 24 
hours. Samples were embedded in paraffin and sectioned at 5μm and stained with haematoxylin and 
eosin (H&E) for histological analysis. To assess the severity or aggressiveness of the tumour 
histologically, the percentage of invasion was estimated at 100 days and end point (death or 500 
days). 
Histological analysis of the prostate gland was performed in accordance with the consensus report 
from the New York meeting of the Mouse Models of Human Cancer Consortium prostate pathology 
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committee[26]. The histological subtype descriptors used were mouse prostate intraepithelial 
neoplasia (mPIN), microinvasive adenocarcinoma and invasive adenocarcinoma.  
Immunohistochemistry, tissue micro-array (TMA) analysis and Western blotting 
Standard immunohistochemistry and western blotting techniques were used throughout this study. 
TMA prostate samples were approved under the Human Tissue Act (HTA) and WCB project 
number 12/007. Full details of the antibodies used and dilutions, staining quantitation methods 
(“Quickscore”) and TMA analysis are provided in the Supplementary Material.  
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Results 
WNT, PI3K and MAPK signalling are elevated in human PCa and are associated with mTORC1 
pathway. 
A number of studies have suggested the importance of WNT, PI3K and MAPK signalling in 
initiation, progression and metastasis of human PCa[1,6,7,10-12] and tissue microarray analysis 
previously showed simultaneous activation of PI3K/AKT and RAS/MAPK signaling in patients 
with late-stage prostate disease[16-19]. To assess the interaction between these pathways and help 
identify a pathway of potential convergence, we analysed human PCa using a tissue microarray of 
317 samples, 244 prostate adenocarcinomas and 73 benign controls (Welsh Cancer Bank). We 
found significant up-regulation of markers associated with activation of all three pathways (WNT, 
PI3K and MAPK signalling) in PCa when compared to benign controls (Fig.1A-C). Furthermore, 
when separating samples based on no/mild staining to moderate/strong staining for downstream 
mTORC1 marker p-S6, there was clear correlation between p-S6 staining and activation of all three 
pathways (Fig.1D-E). Our data therefore suggested that mTORC1 signalling may act as a 
convergence point for these three pathways. 
Pten loss and activation of K-Ras and β-catenin (triple mutants) cooperate to accelerate prostate 
tumourigenesis  
To test the hypothesis that mTORC1 signalling in PCa requires simultaneous activation of WNT, 
PI3K and MAPK pathways, we used an in vivo genetics approach. We generated 8 cohorts of Pb-
Cre4 positive mice carrying different combinations of conditional alleles for Pten loss (Pten
fl/fl
) and 
for -catenin (Catnb+/lox(ex3)) and K-RAS (K-Ras+/V12) activation. These were subdivided into three 
groups according to their genotype: 4 “singles” (WT, Ptenfl/fl, Catnb+/lox(ex3) and  K-Ras+/V12), 3 
“doubles” (Catnb+/lox(ex3)K-Ras+/V12, Ptenfl/flK-Ras+/V12, Catnb+/lox(ex3)Ptenfl/fl) and a “triple” 
(Catnb
+/lox(ex3)
Pten
fl/fl
K-Ras
+/V12
). 15 animals from each cohort were aged until they reached 
Jefferies et al  PTEN, K-RAS and -catenin in prostate cancer 
 
8 
 
specified endpoints or 500 days, which ever was sooner. Additional mice were humanely killed for 
histological and western blotting analysis at 100 days (n=6) and at timepoints of 70, 100, 200, 250 
(Pten
fl/fl
K-Ras
+/V12
 only), 300, 350 (Pten
fl/fl
 only) and 400 days to weigh prostates in order to 
estimate increasing tumour burden over time (n=3). 
All wild-type (WT) and Pb-Cre4
+
K-Ras
+/V12
 single mutant mice survived until the end of the 
experiment (500 days). As previously reported[13] and similar to K-Ras
+/D12 
expressed alone[16-
19] K-Ras
+/V12
 mice did not produce PCa, with all mice surviving to the end of the experiment (500 
days). All other mouse models developed extensive invasive adenocarcinoma of the prostate (100% 
incidence) resulting in ureteric or bladder outflow obstruction secondary to the local effects of the 
primary tumour. Consistent with reports from others[13,27], activation of β-catenin (Pb-
Cre4
+
Catnb
+/ex3
) or homozygous deletion of Pten (Pb-Cre4
+
Pten
fl/fl
) resulted in a reduced median 
survival of 383 days (Range 339-476) and 407 days (Range 350-479) respectively (Fig.1F). 
All double mutant mice had reduced survival when compared to single mutants (p<0.0001, Log-
Rank) (Fig.1F). Mice with activation of both β-catenin and K-RAS  (Pb-Cre4+Catnb+/ex3K-Ras+/V12) 
had a median survival of 182 days (Range 170-208), as reported previously[13]. Mice with loss of 
Pten and activation of β-catenin (Pb-Cre4+Catnb+/ex3Ptenfl/fl) had a median survival of 140 days 
(Range 109-181). Mice with both Pten loss and activation of K-RAS (Pb-Cre4
+
Pten
fl/fl
K-Ras
+/V12
) 
had median survival that was reduced to 238 days (Range 200-292, p<0.0001, Log-Rank; this is 
longer than in models using the more aggressive K-Ras
+/D12
: 20 and 40 weeks median survival are 
reported for Pten
fl/fl
K-Ras
+/D12
 and Pten
+/fl
K-Ras
+/D12
 respectively)[16-19]. Compared to double 
mutants, however, triple mutant mice with Pten loss in addition to activation of β-catenin and K-
RAS (Pb-Cre4
+
Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12
) demonstrated significantly earlier morbidity and 
mortality with a median survival of 96 days (n = 15; Range 76-130, p<0.0001, Log-Rank) (Fig.1F). 
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Tumour progression occurs in a stepwise fashion similar to that of human disease from mouse PIN 
(mPIN) to invasive adenocarcinoma  
All tumour models examined demonstrated stepwise progression from mouse prostate 
intraepithelial neoplasia (mPIN) to microinvasive and invasive adenocarcinoma (Fig.2) as the 
cohorts aged (as shown by analysis of mice at day 70 – day 400 timepoints).  
Histologically normal prostates from wild type (WT) mice (Fig.2A-C) showed avid androgen 
receptor (AR) staining of luminal epithelial cells as well as some stromal reactivity (Fig.2B) and 
had an intact basal layer confirmed by positive cytokeratin (CK) 5 staining (Fig.2C). mPIN was 
characterised by increased cell proliferation within the glands with frequent cellular atypia 
(Fig.2D). There was positive nuclear AR staining (Fig.2E) of the luminal cells and positive 
membranous CK5 staining of the basal layer (Fig.2F). Lesions were classified as microinvasive 
adenocarcinoma when the normal glandular structure showed distortions with some epithelial cells 
invading into the surrounding stroma (typically <1mm). At the site of such invasion there was a 
breach in the basal layer with local loss of basal cell marker CK5 but positive AR staining of the 
cells invading the stroma (Fig.2G-I). Similarly to human PCa, invasive adenocarcinoma of mouse 
prostate exhibited widespread loss of CK5 positivity and the whole basal layer was breached 
allowing invasion of epithelial cells into the stroma (Fig.2J-L and Supplementary Fig.S1A-C). 
Tumours were rapidly proliferating with frequent mitoses and rare apoptotic bodies (Supplementary 
Fig.S1A,B). As the tumours progressed, the prostate glandular architecture became increasingly 
distorted as glands fused together and areas of cribriform pattern formed, pathognomonic of 
Gleason pattern 4 (Fig.2J & Supplementary Fig.S1B). Furthermore, features of Gleason pattern 5 
developed; with single PCa cells appearing in the stroma (Supplementary Fig.S1C). 
All tumour models investigated displayed reactive stroma and regions with mesenchymal 
morphology (spindle shaped cells that can be classified as sarcomatoid metaplasia) adjacent to 
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epithelial areas with mPIN and invasive adenocarcinoma (Supplementary Fig.S1D). Abnormal 
differentiation was evident from regions staining for both epithelial (pan-cytokeratin, pCK) and 
mesenchymal (vimentin) IHC markers (Supplementary Fig.S1E,F). 
In all models where a mutated β-catenin allele was present, squamous metaplasia characterised by 
epithelial-like tumour cells acquiring a squamous morphology and focal areas of 
hyperkeratinisation (‘keratin pearls’; Supplementary Fig.S1G) was common, consistent with 
previous observations in mouse PCa models with activated WNT[13,15,28-31]. Areas of squamous 
metaplasia stained strongly for the basal keratin CK5 (Supplementary Fig.S1H), in contrast to 
prostate adenocarcinoma (Fig.2L). 
Combinatorial pathway mutations shifts the spectrum of lesions to a more aggressive phenotype 
To compare progression of disease between different mouse models, we assessed the percentage of 
invasive adenocarcinoma within each mouse cohort at a fixed timepoint of 100 days 
(Supplementary Fig.S2).  As expected, WT and single K-Ras
+/V12
 mutant mice had histologically 
normal prostates at this time.  Single Catnb
+/ex3
 and Pten
fl/fl
 mice, and Catnb
+/lox(ex3)
K-Ras
+/V12
 mice, 
displayed areas of mPIN but no invasion at 100 days. Pten
fl/fl
K-Ras
+/V12
 and Catnb
+/lox(ex3)
Pten
fl/fl
 
double mutant mice predominately showed mPIN with areas of microinvasive adenocarcinoma at 
100 days (particularly the latter cohort), while triple mutants had widespread invasive 
adenocarcinoma. To assess the rate of growth of tumours, tumour burden was estimated by 
weighing prostates of mice killed at 70, 100, 200, 250 (Pten
fl/fl 
K-Ras
+/V12
 only), 300, 350 (for 
Pten
fl/fl
 only) and 400 days (Supplementary Fig.S3). Prostate weights in Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12
 
triple mutants increased rapidly from the earliest timepoint; Catnb
+/lox(ex3)
Pten
fl/fl
 prostates showed a 
similar behaviour. The other cohorts either showed a delay before tumour growth or there was little 
or no increase in prostate weight at all (in the WT and K-Ras
+/V12
 mice; Supplementary Fig.S3). 
These growth patterns were reflected by proliferation within tumours as analysed by Ki67 staining 
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and BrdU labelling (Supplementary Fig.S4). Triple mutant mice had a significantly higher 
percentage of Ki67+ cells compared to all other genotypes at 100 days. By the experimental 
endpoint, proliferation in the triple mutants (by either Ki67 or BrdU) was still significantly higher 
than the WT and all the single mutant cohorts.  However, proliferation in the double mutants at their 
endpoints was similar to that of the triple mutant mice at endpoint (the differences in proliferation at 
endpoint between Pten
fl/fl
K-Ras
+/V12
 and Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12
 mice by Ki67 and between 
Catnb
+/lox(ex3)
Pten
fl/fl
 and Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12
 mice by BrdU being not significant; 
Supplementary Fig.S4). The rate of apoptosis was low (<1%) across all tumours with no significant 
difference between genotypes (Supplementary Fig.S5).  
Triple mutant mice therefore had faster growing tumours with a more aggressive histological 
phenotype and an increased amount of invasive adenocarcinoma resulting in significantly reduced 
survival when compared to double and single mutant mice. 
Both K-Ras and β-catenin mutations drive metastatic spread in the context of loss of Pten 
To assess metastatic potential in the mouse, retroperitoneal lymph nodes were harvested for each 
genotype and assessed histologically for metastasis (Fig.3). We observed metastatic deposits only in 
two cohorts: 10% (n=1/10) of Catnb
+/ex3
Pten
fl/fl 
and 60% (n=6/10) of Pten
fl/fl
K-Ras
+/V12
 double 
mutant mice demonstrated nodal metastasis (Supplementary Table S1). All metastatic lymph nodes 
examined had areas of neoplastic prostatic epithelium located at the capsule of the node, with fusion 
of glands and a cribriform pattern (Fig.3A), morphologically similar to that seen in the 
corresponding prostate tumour specimens and strongly positive for pan-cytokeratin (Fig.3B). 
 
Triple mutation perturbs “checks and balances” of mTOR signalling regulation in mouse prostate 
To assess whether the accelerated rate of tumour formation and rapid progression in the triple 
mutant mice was due to a synergistic effect between WNT, PI3K/AKT/mTOR and MAPK 
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pathways, we assessed β-catenin levels and localisation, as well as key readouts of 
PI3K/AKT/mTOR and MAPK pathways, in prostate tissue of all cohorts by semi-quantitative 
immunohistochemistry on aged mice (Fig.4&5, Supplementary Fig.S6&S7) and western blot on 
100 day old mice (Fig.6; Supplementary Fig.S8). 
β-catenin localisation in aged mice was primarily at the cell membrane in prostates of WT, Ptenfl/fl, 
K-Ras
+/V12
 and Pten
fl/fl
K-Ras
+/V12
 mutant mice (Fig.4A,D,J,M; Fig.5D), although some nuclear 
localisation was observed (Fig.4N). Nuclear localisation of β-catenin in Ptenfl/flK-Ras+/V12 mice was 
largely associated with invasive areas (Fig.5D) possibly due to relocalisation from cell membrane 
of invading cells after E-cadherin loss[32]. In single, double and triple mutant mice expressing 
Catnb
+/ex3
, there was a significant increase in nuclear localisation of β-catenin (Fig.4G, N; 
Fig.5.A,G,J) but there was lower β-catenin nuclear staining in cohorts in which Pten had been 
knocked out but β-catenin was wild type (Fig.4N, Supplementary Table S2). Overall β-catenin 
levels as measured at 100 days were largely stable (Fig.6 and Supplementary Fig.S8), possibly due 
to negative feedback loops regulating WNT signalling[33,34], but in animals carrying a mutant K-
Ras
+/V12
 but β-catenin wild type, we observed a >2-fold decrease in total β-catenin levels (relative 
levels of β-catenin: WT=1, K-Ras+/V12 = 0.44, p<0.05, Ptenfl/flK-Ras+/V12 = 0.43, p=0.05, Fig.6 and 
Supplementary Fig.S8). 
AKT activation by phosphorylation at both regulatory residues was present at 100 days in all 
cohorts with Pten ablation and to a lesser extent in Catnb
+/ex3
K-Ras
+/V12 
mice  (relative levels of p-
AKT
Thr308
: WT=1, Pten
fl/fl 
=13.89, Pten
fl/fl
K-Ras
+/V12 
= 14.88, Pten
fl/fl
Catnb
+/ex3 
= 6.04; Catnb+/ex3K-
Ras
+/V12
=1.89, Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12
=7.62; p-AKT
Ser473
: WT=1, Pten
fl/fl 
=12.76, Catnb
+/ex3
K-
Ras
+/V12
=2.90, Catnb
+/ex3
Pten
fl/fl
= 16.72, Pten
fl/fl
K-Ras
+/V12
=20.53, Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12
= 
9.36; for all comparisons p<0.01 relative to WT; Fig.6 and Supplementary Fig.S8). This was 
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confirmed by p-AKT
Thr308
 staining of aged prostates (Fig.4B,E,H,K and Fig.5B,E,H,K,M; 
SuppTable 1). 
AKT is known to inhibit GSK3β activity by phosphorylating Ser9 residue[35], which can serve as 
readout of AKT activity. Although GSK3β is a part of β-catenin destruction complex, AKT-
dependent Ser9 phosphorylation is not likely to affect WNT signalling, but rather TSC1/2[36].  
Phospho-GSK3βSer9 levels in prostates from aged mice (Supplementary Fig.S6) largely correlated 
with AKT activation, with staining detected only in cohorts with deleted Pten and in Catnb
+/ex3
K-
Ras
+/V12
 mice (Supplementary Fig.S6). Prostates from the Catnb
+/ex3
Pten
fl/fl
 and Catnb
+/ex3
Pten
fl/fl
K-
Ras
+/V12
 cohorts had significantly higher levels of p-GSK3βSer9 compared to all other cohorts 
(Supplementary Fig.S6H,I). 
Total levels of p-ERK1/2 (p44/42 MAPK) were lower in 100 day old K-Ras
+/V12 
mice and all other 
tumour models when compared with age matched WT animals by western blot (WT=1, K-
Ras
+/V12
=0.27, p<0.01, Fig.6 and Supplementary Fig.S8). Although these findings are surprising at 
face value, the ERK-signalling network has numerous negative feedback loops[37] and when Pten 
was deleted and -catenin activated, K-Ras+/V12 expression led to a 7.2-fold increase in p-ERK1/2 
levels (Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12
 vs Catnb
+/ex3
Pten
fl/fl
, p<0.01, Fig.6 and Supplementary Fig.S8), 
although this still did not fully rescue WT levels. However, immunostaining of aged prostates for p-
ERK1/2 revealed that while WT mice tended to have moderate, uniform staining, tumour models 
were more heterogeneous with areas of focal strong staining which cannot be distinguished in 
western blot (Supplementary Fig.S7). Indeed, by Quickscore, aged WT and K-Ras
+/V12 
mice had 
similar levels of p-ERK1/2 and all other models had significantly higher p-ERK1/2 levels 
(Supplementary Fig.S7I). 
Finally, ribosomal protein S6 phosphorylation is a key readout of mTORC1 activity[38].  Western 
blot analysis of younger (100 day old) mice revealed that only the triple Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12 
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mice showed significantly increased levels of p-S6
240-244
 (WT=1, Catnb
+/ex3
K-Ras
+/V12
 = 0.49, 
Catnb
+/ex3
Pten
fl/fl
 = 0.69, Pten
fl/fl
K-Ras
+/V12
 = 0.47, Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12 
= 2.09, p<0.01; Fig.6 
and Supplementary Fig.S8). This 3-4-fold increase in p-S6
240-244
 levels observed in the triple 
compared to the double mutant mice suggests the abrogation of negative feedback loops controlling 
mTORC1. Furthermore, prostate tissue from aged Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12 
mice also had 
significantly higher levels of p-S6
240-244
 compared to aged mice of other genotypes (p<0.05 
compared to the next closest genotype; Fig.4C,F,I,L, Fig.5C,F,I,L,N).  
Therefore, our study supports the hypothesis that mTORC1 signalling in PCa requires simultaneous 
activation of WNT, PI3K and MAPK pathways, as suggested by the human TMA data, and that this 
results in a more aggressive tumour phenotype. Furthermore, it suggests that the parallel activation 
of WNT, PI3K/AKT/mTOR and MAPK signalling has its synergistic effect due to relieving 
multiple negative feedback loops and cross-talks between the pathways. 
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Discussion 
Although the androgen signalling pathway and ADT are pivotal in the treatment of advanced PCa, 
men still relapse with CRPC. Given the importance of feedback within signaling networks, it is 
important to understand the potential outcomes of cross-talk between key signaling modules within 
the prostate and possible implications for CRPC. For example, androgen depletion leads to 
PI3K/AKT pathway stimulation[39] and increased nuclear co-localization and interaction of 
endogenous AR and β-catenin[40]. Our study provides evidence of clear synergistic crosstalk 
between the WNT, PI3K/AKT and MAPK signalling pathways driving progression in prostate 
tumourigenesis.   
Transcriptional alterations in both PI3K/AKT and MAPK are common in PCa, particularly in 
metastatic tumours[1]. These two pathways are regulated by a number of cross-talks including both 
activating and inhibitory loops[41].  RAS can directly bind to and activate PI3K[42]. The TSC1/2 
complex, a key suppressor of PI3K-dependent stimulation of mTOR[43], can be inhibited by 
oncogenic MAPK signalling through both ERK and ribosomal S6 kinase (RSK)-dependent 
phosphorylation, resulting in increased mTORC1 signalling[44]. Furthermore, both ERK[44] and 
RSK [45,46] have been shown to directly phosphorylate Raptor to enhance mTORC1 activity. AKT 
negatively regulates ERK activation by phosphorylating inhibitory sites in the RAF N-terminus[47], 
ERK phosphorylation inhibits RAF and MEK[48] and phosphorylation of the downstream 
mTORC1 effector S6K feeds back to inhibit AKT activity and in turn mTORC1 signalling[49]. 
mTORC1 inhibition in turn activates MAPK signalling through a PI3K-dependent feedback 
loop[50]. We illustrate the multitude of regulatory links between PI3K/AKT and MAPK in 
Supplementary Fig.S9.  
Complex interactions between androgen depletion, PI3K/AKT/mTOR and MAPK pathways have 
therapeutic implications. mTORC1 signalling is emerging as a key pathway that directs ADT 
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resistance and stimulates tumour growth in the setting of castrate levels of testosterone (CRPC)[51]. 
The importance of mTORC1 signalling has resulted in the development of inhibitors such as 
rapamycin and its analogues, including everolimus and temsirolimus. Early studies with these 
inhibitors in PCa demonstrated regression of PIN lesions in a mouse model overexpressing 
AKT[52] and inhibition of growth of xenograft models derived from human cells lines with Pten 
loss[53]. Despite these promising preclinical results and the success of mTORC1 inhibitors in the 
treatment of patients with metastatic renal cell carcinoma[54], the clinical use of mTORC1 
inhibitors in men with metastatic PCa has been disappointing. Phase I/II trials using single agent 
such as rapamycin or everolimus, have failed to show anti-tumour effects with little response in 
PSA or clinical progression[55,56]. The lack of therapeutic effects can be ascribed to MAPK 
pathway activation through a PI3K-dependent feedback loop in prostate tumours of patients treated 
with mTOR inhibitors[50].  Dual PI3K/mTORC1/2 drugs such as BEZ235 (Novartis) have shown 
positive effects in overcoming Docetaxel resistance in pre-clinical studies[57] and in mouse 
xenograft models[58]. Although BEZ235 has been discontinued in PCa, the results have stimulated 
a search for agents targeting PI3K/AKT/mTOR signalling with more favourable therapeutic 
index[59]. 
WNT signalling can integrate with both the PI3K/AKT/mTOR and MAPK pathways either directly 
via the GSK-3β-TSC2 axis or indirectly via -catenin-dependent canonical WNT signalling, 
stimulation of c-Myc transcription and inhibition of MAPK-stimulated senescence pathways 
(Supplemental Fig.S9)[60,61] or through -catenin interactions with AR[40]. In the absence of a 
WNT signal, GSK-3β phosphorylates -catenin as part of the destruction complex. When WNT 
signalling is activated, GSK-3β is sequestrated in multivesicular endosomes allowing β-catenin to 
accumulate[62]. GSK-3β can also phosphorylate TSC2 and promote TSC1/2 activity, therefore, 
WNT-dependent inhibition of GSK3β may stimulate mTOR signalling as well as canonical WNT 
pathway activation[60]. 
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Furthermore, phosphorylation of GSKβ by AKT or ERK can also result in TSC1/2 activation[36] or 
β-catenin–dependent WNT signalling[61], respectively. GSKβ is known to interact with p53[63] 
and p53 is implicated in negative feedback loops controlling cell growth through restraining WNT 
signalling[34]. In some models, Pten-deficient mouse prostates exhibit activated p53 and 
senescence[64] and the RAS/RAF axis also can stimulate p16/p21/p53-dependent senescence in a 
variety of tissues[65]. Consistent with the convergence of these three pathways on mTORC1, and 
feedback loops and cross-talks regulating them, only simultaneous deregulation of the PI3K, WNT 
and MAPK pathways resulted in significantly elevated mTORC1 signalling in our mouse models. 
Importantly, in our models, canonical WNT signalling was activated at the level of -catenin, not 
further up the pathway, for instance by deletion of APC[30,66]. Collapse of the -catenin 
destruction complex following APC loss will not only lead to -catenin stabilisation but may also 
free GSK-3 to phosphorylate targets such as TSC2. In our system the presence of an activated -
catenin was sufficient to drive synergistic crosstalk with the PI3K/AKT and MAPK pathways. This 
has allowed us to isolate the specific role of -catenin transcriptional activity. 
Our findings are consistent with previous studies using similar animal models with single or double 
conditional alleles. However, we do see some differences. Some authors have reported senescence 
in models in which Pten alone was knocked-out in a prostate-specific manner[18,64], however, this 
is not true of all models[15] and we did not observe this. The differences may be due to background 
strain or the particular conditional allele being used. As previous authors reported[15], combined β-
catenin activation and Pten deletion led to accelerated tumour growth, increased invasive ability 
and squamous differentiation. We found one incidence of metastasis with this combination, unlike a 
previous study which had no indication of metastases[15] but which culled mice at an earlier age 
than in our study. Activated β-catenin is likely to drive proliferation of invading cells and primary 
tumour growth but not metastasis as such, leading to death from primary tumour morbidity. The one 
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Catnb
+/ex3
Pten
fl/fl
 mouse showing a metastasis is likely to have resulted from chance combination of 
rapid invasion of tumour cells with a longer lifespan. 
We observed greater metastatic incidence in the Pten
fl/fl
K-Ras
+/V12
 model than in Catnb
+/ex3
Pten
fl/fl
 
mice. Pten
fl/fl
K-Ras
+/V12
 mice had a longer survival than the more aggressive Pten
fl/fl
K-Ras
+/D12 
model described previously[16], but consistent with our findings macrometastatic lesions were 
reported in all Pten
fl/fl
K-Ras
+/D12 
and Pten
fl/+
K-Ras
+/D12 
mice. The more extensive nature of the 
metastases and their rapid development is likely to result from the use of the more aggressive K-
Ras
+/D12 
allele. Interestingly, some evidence of the presence of recombined alleles was detected in 
bone, but overt bone metastasis were not observed[16]. In a PCa model in which Cre was driven 
from a knock-in to the Nkx3.1 promoter, the combination of BRAF
V600E
 activation with Pten 
deletion resulted in animal lethality comparable to Pten
fl/fl
K-Ras
+/D12
, with an extensive metastatic 
burden and was associated with elevated c-MYC activity[17]. In contrast to both our observations 
on K-Ras
+/V12 
and previous data on K-Ras
+/D12
[16], activation of BRAF
V600E
 alone stimulated cell 
proliferation[17]. Importantly, however, NKX3.1 is a negative regulator of c-MYC transcriptional 
activity, and the Nkx3.1-Cre knock-in has a haplo-insufficient phenotype with elevated basal levels 
of c-MYC activity[67]. Analysis of this model is therefore confounded by use of the the Nkx3.1-Cre 
knock-in and the role of c-MYC, which may be mimicking, at least partly, an activated -catenin. 
Nevertheless, although mutant BRAF and KRAS belong to the same signalling axis, the differences 
between the models suggest their activation has different implications, particularly for proliferation. 
Taken together, these studies imply a distinct role for KRAS activation combined with Pten 
deletion in promoting prostate metastasis. It is likely that reason we did not observed metastasis in 
our triple mutant model is simply that the animals succumbed so rapidly to the growth of the 
primary tumour. 
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This study has limitations. The differences in prostate anatomy between mouse and human mean 
that the interactions of mouse prostate tissue with the microenvironment may be different between 
the species (and indeed different in different lobes), affecting neoplastic processes. More 
importantly, the main cause of death in human PCa is metastasis, typically to the bone, whereas 
mouse models of PCa need to the euthanased as a result of locally advanced tumours. Indeed, 
despite increased PI3K, WNT, MAPK and mTORC1 signalling, triple mutant mice did not develop 
lymph node metastasis. This is likely due to the rapid progression of the primary tumour not 
allowing necessary time for metastasis to develop. One model, Pten
fl/fl
K-Ras
+/V12
, did develop 
lymph node metastases in >50% of animals, consistent with previous reports[16]. However, they 
still had to be euthanased as a result of locally advanced prostate tumours. It is unclear whether, 
even in the models which show lymph node metastasis, dissemination to organs or bone would ever 
happen. There are few autochthonous mouse models of any cancer driven by genetic lesions 
mimicking human disease which spontaneously develop overt bone metastases, although SV40 T-
antigen models can do so[68] and in Pten
fl/fl
K-Ras
+/D12
 mice recombined cells were detected in 
bone[16]. Therefore, there remains a lack of mouse models that truly mimic advanced PCa.  
In summary, we show that the PI3K, WNT and MAPK signalling pathways co-operate to accelerate 
prostate tumourigenesis and activate mTORC1 signalling, one of the key drivers of resistance to 
ADT. Our findings suggest that in addition to PI3K pathway inhibition, AR inhibitors could be 
combined with either MAPK or WNT pathway inhibitors with therapeutic benefit in CRPC. 
However, although mTORC1 may be difficult to activate as a result of dysregulation of a single 
pathway, once activated it may require intervention of more than one pathway to inhibit its activity, 
or, indeed, to prevent feedback loops from activating other oncogenic pathways[50]. Our triple 
mutant mouse model provides an excellent system for pre-clinical studies of multiple pathway 
inhibition as a therapeutic approach to targeting mTOR.  
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Figure Legends 
Figure 1: Immunohistochemistry for WNT, PI3K, MAPK and mTOR pathway markers in a 
human prostate cancer tissue-micro-array (TMA) and Kaplan-Meier survival curves for in 
vivo genetic models.  (A, B, C) Immunohistochemistry for expression of markers of WNT (A), 
PI3K (B) and MAPK (C) pathway activation in human PCa TMA demonstrating higher activity (as 
assessed by mean Quickscore) in cancer when compared to benign prostatic tissue. (D) Assessment 
of WNT pathway activation marker staining as a function of phospho-S6 staining (p-S6; no/mild 
versus moderate/strong staining, using mean Quickscore) demonstrating positive correlation of 
nuclear β-catenin and c-MYC with increased p-S6 staining. (E) Assessment of PI3K and MAPK 
pathway activation marker staining as function of p-S6 staining demonstrating positive correlation 
of all markers (p-AKT, p-MTOR, p-ERK and p-MEK) with increased p-S6 staining.  Error bars = 
mean with 95% CI, Unpaired T test: *p<0.05, **p<0.01. (F) Kaplan-Meier survival curves for 
mouse models (top) and statistical analysis (bottom). The median survival for triple mutant (Pb-
Cre4
+
 Catnb
+/ex3
Pten
fl/fl 
K-Ras
+/V12
) mice was significantly lower than double mutants (p<0.0001, 
Log- Rank): 96 days (range 76-130), compared to 238 days (range 200-292), 182 days (range 170- 
208) and 140 days (range 109-181) for the double mutants: Pb-Cre4
+
 Pten
fl/fl
 K-Ras
+/V12
, Pb-Cre4
+
 
Catnb
+/ex3
 K-Ras
+/V12
 and Pb-Cre4
+
 Catnb
+/ex3
Pten
fl/fl
, respectively. All double mutant combinations 
had a significantly shorter survival when compared to single mutants (p<0.0001, Log-Rank). The 
survival of Pb-Cre4
+
 Catnb
+/ex3
 and Pb-Cre4
+
 Pten
fl/fl
 was 383 days (range 339-476) and 407 
(range 350-479), respectively. Pb-Cre4
+
 K-Ras
+/V12
 and wild-type mice all survived to the end-
point of the experiment (500 days). Wild-type (WT), Catnb
+/ex3
 (β-catenin).  
 
Figure 2:  Histological characterisation of normal, mouse prostate intraepithelial neoplasia 
(mPIN), microinvasive adenocarcinoma and diffuse adenocarcinoma of the mouse prostate. 
(A) Hematoxylin and eosin (H&E) staining of the histologically normal prostate gland. (B) 
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Androgen receptor (AR) immunohistochemistry demonstrates avid staining of the luminal cells 
with (C) cytokeratin (CK) 5 staining the membrane of the basal layer abutting the basement 
membrane in a continuous fashion. (D) mPIN has a characteristic appearance with increased cell 
proliferation within the glands with frequent cellular atypia. (E,F) mPIN lesions display widespread 
AR staining (E) while the CK5 staining remains continuous (F). (G) In microinvasive 
adenocarcinoma, the glandular structure begins distort with focal areas of microinvasion of AR 
positive (H) epithelial cells into the surrounding stroma. (I) At the site of invasion there is loss of 
the continuous CK5 staining basal layer. (J) H&E staining of prostate adenocarcinoma sections 
demonstrate diffuse invasion of epithelial cells into the stroma, with fusion of glands and areas of 
cribriform pattern, which is pathognomonic of human Gleason pattern 4. (K) AR staining 
demonstrates intensely stained epithelial cells invading the stroma with loss of the basal marker 
CK5 (L). Bars = 200 m. Insets magnified two times. 
 
Figure 3:  Lymph node characterisation. (A) Metastatic prostate epithelium extending from the 
capsule (black arrow) and infiltrating into the node (red-dotted line). (B) Metastatic node staining 
avidly for pan-cytokeratin. (C) Benign reactive node with the inner medulla (M) and outer cortex 
(C) separated by the dotted black line. The capsule and marginal sinus (black arrow) surrounds the 
node with the cortex separated by cortical sinuses (red arrow). Germinal center within the cortex of 
the node (*). (D) Minimal non-specific pan-cytokeratin staining in a benign node. Scale bars as 
indicated. 
 
Figure 4: Immunohistochemistry for β-catenin, p-AKTThr308 and p-S6240-244 in wild type and 
single allele mouse models. (A-L) Immunostaining using antibodies against β-catenin (A, D, G, J), 
p-AKT
Thr308
 (B, E, H, K), and p-S6
240-244
 (C, F, I, L) on WT (A-C), Pb-Cre4
+
 Pten
fl/fl 
(D-F), Pb-
Cre4
+
 Catnb
+/ex3
(G-I) and Pb-Cre4
+
 K-Ras
+/V12
 (J-I) cohorts of mice (n=4) at the endpoint of the 
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experiment (500 days or when sick). Bars = 200 m. Insets magnified two times. (M, N) 
Quickscore quantification of β-catenin membrane-specific (M) and nuclear staining (N) in all 
genotypes, including staining presented in Fig.5. Note Quickscore quantitation of p-AKT
Thr308
 and 
p-S6
240-244
 for all genotypes is presented in Fig.5M and N. For clarity, significance of Quickscore 
staining in triple mutant vs double mutant cohorts only is presented on the graphs (NS, not 
significant;* P<0.05; ** P<0.01; *** P<0.001; unpaired two-tailed t-test, n=4); full statistical 
comparisons of all genotypes are given in Supplementary Table 1. WT prostates demonstrated 
predominantly membranous staining for β-catenin, with some nuclear staining, but no p-AKTThr308 
or p-S6
240-244
 reactivity (A-C). Pten
fl/fl 
tumours had membrane staining for β-catenin, rare nuclear 
positivity, diffuse staining for p-AKT
Thr308
 and focal staining for p-S6
240-244
 (D-F). Catnb
+/ex3
 
tumours had strong nuclear staining of β-catenin, with reduced cell membrane staining, and focal 
positive staining for p-AKT
Thr308
 and p-S6
240-244
 (G-I). K-Ras
+/V12
 samples had predominantly 
membrane staining for β-catenin with some nuclear positivity and no staining for p-AKTThr308 or p-
S6
240-244
 (J-L).  
 
Figure 5: Immunohistochemistry for β-catenin, p-AKTThr308 and p-S6240-244 in double and 
triple allele mouse models. (A-L) Immunostaining for β-catenin (A, D, G, J), p-AKTThr308 (B, E, 
H, K), and p-S6
240-244
 (C, F, I, L) on Pb-Cre4
+
 Catnb
+/ex3
 K-Ras
+/V12
 (A-C), Pb-Cre4
+
 Pten
fl/fl 
K-
Ras
+/V12
 (D-F), Pb-Cre4
+
 Catnb
+/ex3
Pten
fl/fl 
(G-I) and Pb-Cre4
+
 Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12
 (J-L) 
cohorts of mice (n=4) at the endpoint of the experiment (500 days or when sick. Bars = 200 m. 
Insets magnified two times. (M, N) Quickscore quantification of p-AKT
Thr308
 and p-S6
240-244
 for all 
genotypes. For Quickscore quantification of β-catenin membrane-specific (M) and nuclear staining 
(N), see Fig.4M,N. For clarity, significance of Quickscore staining in triple mutant vs double 
mutant cohorts only is presented on the graphs (NS, not significant;* P<0.05; ** P<0.01; *** 
P<0.001; unpaired two-tailed t-test, n=4); full statistical comparisons of all genotypes are given in 
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Supplementary Table 1. Catnb
+/ex3
K-Ras
+/V12
 tumours demonstrated predominantly nuclear staining 
of β-catenin, with weak focal staining for p-AKTThr308 and p-S6240-244 (A-C).  Ptenfl/fl K-Ras+/V12 
tumours had strong membrane staining for β-catenin, strong diffuse staining for p-AKTThr308 and 
focal positive staining for p-S6
240-244
 (D-F). Catnb
+/ex3
Pten
fl/fl
 tumours demonstrated both nuclear 
and membrane-specific β-catenin staining, diffuse staining for p-AKTThr308 and focal positive 
staining for p-S6
240-244
 (G-I). Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12
 tumours stained avidly for nuclear β-
catenin with diffuse strong staining for both p-AKT
Thr308
 and p-S6
240-244
 (J-L), the latter being 
significantly higher than in all other cohorts. 
 
Figure 6: Biochemical analysis of signalling pathways in prostate tissue from double and 
triple allele models. (A) Western-blot analysis of markers of activation of the PI3K, WNT, MAPK 
and mTOR signalling pathways for Wild-type (WT), double (Catnb
+/ex3
K-Ras
+/V12
, 
Pten
fl/fl
Catnb
+/ex3
 and Pten
fl/fl
K-Ras
+/V12
) and triple (Catnb
+/ex3
Pten
fl/fl
K-Ras
+/V12
) mutants. Protein 
was extracted from fresh frozen prostate tissue from 100-day old mice for each cohort (n=3). The 
following antibodies were used: PI3K pathway markers, PTEN, p-AKT
Thr308
, p-AKT
Ser473
 and total 
AKT; WNT pathway marker, β-catenin; MAPK pathway marker, pERK1/2; mTOR pathway 
markers, p70S6K and pS6
240/244. β-actin was used as a loading reference. (B–F) Relative 
quantitation of p-AKT
Thr308
 (B), pAKT
Ser473
 (C), β-catenin (D), p-ERK1/2 (E) and p-S6240/244 (F).  
Error bars = mean with 95% CI, *p<0.05, **p<0.01, unpaired two-tailed t test, n=3. 
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Supplementary Material for Online Publication Only 
Consists of twelve files: 
 
One Supplementary Information document 
Supplementary Materials and Methods 
Figure Legends for Supplementary Figures 
 
Nine Supplementary Figures 
Supplementary Figure S1: Histological characterisation of invasive adenocarcinoma, 
reactive stroma and squamous metaplasia in Catnb
+/ex3
Pten
fl/fl 
K-Ras
+/V12
 triple mutant 
prostate tumours. 
Supplementary Figure S2: Percentage of invasive adenocarcinoma.  
Supplementary Figure S3: Rate of growth of prostate tumours. 
Supplementary Figure S4: Proliferation of prostatic lesions by Ki67 and BRDU staining.  
Supplementary Figure S5: Rate of apoptosis according to percentage (%) of Caspase-3 
positivity at endpoint (500 days or when sick). 
Supplementary Figure S6: Immunohistochemistry for p-GSKβSer9 for all mouse models. 
Supplementary Figure S7: Immunohistochemistry for p-ERK 1/2 for all mouse models. 
Supplementary Figure S8: Biochemical analysis of signalling pathways in in wild type and 
single allele prostate tissue. 
Supplementary Figure S9: Complex interactions between PI3K, Wnt and MAPK pathways 
resulting in aberrant mTORC1 signalling. 
One Supplementary Table 
Supplementary Table S1: Percentages of animals with nodal metastasis. 
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Supplementary Table S2: Full statistical comparisons (unpaired t-tests, n = 3) for 
Quickscore quantitations. 
